logo
logo

Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders

Neurogastrx Secures $60 Million In Series B Financing And Expands Management Team To Advance Its Pipeline Of Transformative Investigational Therapies For Gastrointestinal Disorders

08/26/21, 10:34 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/US.svgwoburn
Money raised
$60 million
Round Type
series b
Neurogastrx, Inc., a privately held specialty pharmaceutical company developing transformative therapies for gastrointestinal (GI) disorders, announced today the successful completion of a $60 million Series B crossover round led by Vivo Capital. Other new investors participating in the Series B round include RTW Investments, Samsara BioCapital and Marshall Wace, joining 5AM Ventures, venBio and OrbiMed Advisors who also participated in the Series A financing.

Company Info

Company
Neurogastrx
Location
woburn, massachusetts, united states
Additional Info
Neurogastrx, Inc. is a privately held specialty pharmaceutical company developing transformative therapies to advance the treatment of GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. For more information, visit the company’s website at www.neurogastrx.com.